Singapore, March 13, 2008: The US Food and Drug Administration (FDA) has appointed Dr Janet Woodcock as director of the agency's Center for Drug Evaluation and Research (CDER).
CDER is charged with assuring that safe and effective drugs, including prescription, over-the-counter and generics, are available to Americans.
“Dr Woodcock's outstanding scientific credentials and historical knowledge of the complexities involved in drug safety and regulation make her uniquely qualified to oversee, as well as modernize the techniques, tools, and methods used for evaluating the safety and effectiveness of drugs throughout the product life-cycle,” said Dr Von Eschenbach, Commissioner of FDA.
Dr Woodcock received her Doctor of Medicine from Northwestern Medical School and completed further training and held teaching appointments at the Pennsylvania State University and the University of California in San Francisco.
Throughout her career at the FDA, Dr Woodcock has played an integral role in advancing the health of the American public. Under her strong leadership, the FDA launched the Critical Path Initiative designed to bridge the gap between basic scientific research and the medical product development process. This initiative called for a collaborative cross-sector effort to modernize the drug development process and has resulted in several prominent partnerships looking at a wide variety of scientific issues. Dr Woodcock will continue to be involved in this initiative, as well as the emerging post-market surveillance collaborations with the private sector.
| 
SITE MAP 
Comment on this article
